NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / Technology News / Bharat Biotech signs deal for nasal COVID-19 vaccine: Details here
    Bharat Biotech signs deal for nasal COVID-19 vaccine: Details here
    1/6
    Technology 3 min read

    Bharat Biotech signs deal for nasal COVID-19 vaccine: Details here

    By Shubham Sharma
    Sep 23, 2020
    02:44 pm
    Bharat Biotech signs deal for nasal COVID-19 vaccine: Details here

    In a major move, Bharat Biotech has signed an agreement to license a nasal COVID-19 vaccine developed by the Washington University School of Medicine in St. Louis, United States. The agreement will see the Indian biotech firm manufacture and distribute the novel solution for the deadly respiratory disease across several countries, including our own. Here is all you need to know about the agreement.

    2/6

    What does the agreement entail?

    Under the deal, announced just recently, Bharat Biotech and US-based biotech firm Precision Virologics acquired rights to WUSM's chimp-adenovirus intra-nasal vaccine for COVID-19. The US firm has access to the vaccine technology for supply in the US, Europe, and Japan, while the Indian company will be handling distribution in all other markets, starting with India.

    3/6

    Bharat Biotech will conduct clinical trials in India

    The single dose nasal vaccine has already shown "unprecedented levels of protection in mouse studies" and is cleared for a Phase-1 human trial, which will be conducted at Saint Louis University's Vaccine and Treatment Evaluation Unit. The advanced phases of the clinical study will be carried out in India upon receiving necessary approvals from the Drugs Controller General of India.

    4/6

    Manufacturing at company's India facility

    Along with trials, Bharat Biotech will also be undertaking large-scale manufacturing of the vaccine at its GMP facility in Genome Valley, Hyderabad. "We are proud to collaborate on this innovative vaccine," said Dr. Krishna Ella, the Chairman and MD of Bharat Biotech. "We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen."

    5/6

    Nasal vaccine expected to be more effective, easier to administer

    A single dose nasal vaccine will be easier to administer, which will enable a broader reach while reducing the cost of medical consumables such as syringes. Precision Virologics Interim CEO David T. Curiel says that "it also prevents the spread of the disease by directly targeting the cells that line the nose and throat. Most other vaccine candidates currently under development can't do that."

    6/6

    Bharat Biotech is also making its own homegrown COVID-19 vaccine

    The licensing agreement comes as Bharat Biotech continues to work on its own, homegrown COVID-19 vaccine dubbed COVAXIN. The shot has been proven safe and effective in pre-clinical animal trials, and now, it is moving through the Phase-2 of human trials at multiple sites. The third phase is slated to begin sometime next month, according to recent reports.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Washington University
    Drugs Controller General of India
    Coronavirus
    COVID-19
    Bharat Biotech

    Washington University

    Experts think first COVID-19 vaccines might not prevent infection Bloomberg
    This neurosurgeon wants to connect humans with Internet using brain-implants! Technology
    Nobel Prize: Three scientists win for 'discovering Hepatitis C virus' Nobel Prize

    Drugs Controller General of India

    Coronavirus: What is the 'Feluda' test? How does it work? DNA
    SII gets nod for Oxford COVID vaccine phase 2/3 trials Oxford
    You can enroll for AIIMS's COVID-19 vaccine trials: Here's how All India Institute Of Medical Sciences (AIIMS)
    Expert panel sets conditions, ICMR's COVAXIN August-15 target looks unachievable Indian Council of Medical Research (ICMR)

    Coronavirus

    Emerging coronavirus hotspots identified in Delhi; CP, Lajpat on list Lajpat Nagar
    Donald Trump tears into China for unleashing coronavirus; demands accountability Donald Trump
    Coronavirus: India's tally reaches 56.4 lakh; death toll crosses 90,000 India
    Over one crore migrant workers returned home between March-June: Government Lok Sabha

    COVID-19

    Delhi government order reserving 80% ICU beds stayed by HC Delhi High Court
    Coronavirus: Amid second-wave fears, UK PM to encourage remote working Boris Johnson
    Vaccine expected by early 2021; nationwide immunization a challenge: Scientist Vaccine
    Getting COVID-19 and flu together increases risk of death: Experts University Of California

    Bharat Biotech

    COVAXIN animal trials confirmed to be successful: Details here Coronavirus
    Bharat Biotech gets approval to test COVAXIN administration through skin All India Institute Of Medical Sciences (AIIMS)
    COVAXIN: India's COVID-19 vaccine found safe in early trial All India Institute Of Medical Sciences (AIIMS)
    Israel claims to have 'excellent' COVID-19 vaccine in hand Israel
    Next News Article

    Love Technology News?

    Subscribe to stay updated.

    Science Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023